Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Desmopressin · DIN 02284030
Manufacturer: Apotex Inc.; listing date 2007-04-02
Health Canada: Marketed since 2022-04-07 · brand APO-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.1 MG · company Apotex inc · schedule Prescription
Apo-Desmopressin: Formulary list price $0.6609/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6609 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76960 · Verify on the e-Formulary ↗ (DIN 02284030)
Source record
DIN 02284030: Apo-Desmopressin
Raw flags: sec3=Y
Item: 682800010; group id 790; item number 1926; lccId None; manufacturer id APX
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.6609; ministry $0.6609
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284030
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76960Interchangeable products
DDAVP · DIN 00824305 · $0.6609
PMS-Desmopressin · DIN 02304368 · $0.6609
Shortage status: resolved shortage (ended 2026-03-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284030
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Desmopressin · DIN 02304368 · 0.1mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Desmopressin · DIN 02304368
Manufacturer: Pharmascience Inc.; listing date 2010-04-23
Health Canada: Marketed since 2008-01-23 · brand PMS-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE (DESMOPRESSIN ACETATE TRIHYDRATE) 0.1 MG · company Pharmascience inc · schedule Prescription
PMS-Desmopressin: Formulary list price $0.6609/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.6609 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78965 · Verify on the e-Formulary ↗ (DIN 02304368)
Source record
DIN 02304368: PMS-Desmopressin
Raw flags: sec3=Y
Item: 682800010; group id 790; item number 1926; lccId None; manufacturer id PMS
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.6609; ministry $0.6609
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304368
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78965Interchangeable products
Apo-Desmopressin · DIN 02284030 · $0.6609
DDAVP · DIN 00824305 · $0.6609
Shortage status: discontinued (2017-04-05, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304368
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Desmopressin · DIN 02284049 · 0.2mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Desmopressin · DIN 02284049
Manufacturer: Apotex Inc.; listing date 2007-04-02
Health Canada: Marketed since 2022-04-07 · brand APO-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.2 MG · company Apotex inc · schedule Prescription
Apo-Desmopressin: Formulary list price $1.3217/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3217 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76961 · Verify on the e-Formulary ↗ (DIN 02284049)
Source record
DIN 02284049: Apo-Desmopressin
Raw flags: sec3=Y
Item: 682800011; group id 790; item number 1927; lccId None; manufacturer id APX
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $1.3217; ministry $1.3217
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284049
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76961Interchangeable products
DDAVP · DIN 00824143 · $1.3217
PMS-Desmopressin · DIN 02304376 · $1.3217
Shortage status: resolved shortage (ended 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284049
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Desmopressin · DIN 02304376 · 0.2mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Desmopressin · DIN 02304376
Manufacturer: Pharmascience Inc.; listing date 2010-04-23
Health Canada: Marketed since 2021-11-25 · brand PMS-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE (DESMOPRESSIN ACETATE TRIHYDRATE) 0.2 MG · company Pharmascience inc · schedule Prescription
PMS-Desmopressin: Formulary list price $1.3217/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.3217 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78966 · Verify on the e-Formulary ↗ (DIN 02304376)
Source record
DIN 02304376: PMS-Desmopressin
Raw flags: sec3=Y
Item: 682800011; group id 790; item number 1927; lccId None; manufacturer id PMS
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $1.3217; ministry $1.3217
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02304376
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78966Interchangeable products
Apo-Desmopressin · DIN 02284049 · $1.3217
DDAVP · DIN 00824143 · $1.3217
Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304376
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Desmopressin Spray · DIN 02242465 · 10mcg/Metered Dose · Nas Sp-2.5mL Pk
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Desmopressin Spray · DIN 02242465
Manufacturer: A A Pharma Inc.; listing date 2002-07-29
Health Canada: Marketed since 2011-03-10 · brand DESMOPRESSIN SPRAY · ATC H01BA02 DESMOPRESSIN · form Spray (metered-dose) · route Nasal · ingredients DESMOPRESSIN ACETATE 10 MCG/ACT · company Aa pharma inc · schedule Prescription
Desmopressin Spray: Formulary list price $42.1661/unit (unit not stated in source; not the patient's cost)
Ministry pays: $42.1661 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66190 · Verify on the e-Formulary ↗ (DIN 02242465)
Source record
DIN 02242465: Desmopressin Spray
Raw flags: sec3=Y
Item: 682800006; group id 790; item number 1922; lccId None; manufacturer id AAP
Source form: Nas Sp-2.5mL Pk; strength: 10mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $42.1661; ministry $42.1661
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242465
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66190Interchangeable products
DDAVP · DIN 00836362 · not recorded
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-23, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
DDAVP Melt: Formulary list price $1.4990/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.4990 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77052 · Verify on the e-Formulary ↗ (DIN 02284995)
Source record
DIN 02284995: DDAVP Melt
Raw flags: sec3=Y
Item: 682800026; group id 790; item number 1924; lccId None; manufacturer id FEI
Source form: Orally Disintegrating Tab; strength: 60mcg
Recorded listing: General benefit
Source prices (unrounded): $1.4990; ministry $1.4990
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284995
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77052
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284995
Shortage record checked 2026-09-13T08:10:21.292534+00:00
DDAVP Melt: Formulary list price $2.9990/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.9990 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77053 · Verify on the e-Formulary ↗ (DIN 02285002)
Source record
DIN 02285002: DDAVP Melt
Raw flags: sec3=Y
Item: 682800027; group id 790; item number 1925; lccId None; manufacturer id FEI
Source form: Orally Disintegrating Tab; strength: 120mcg
Recorded listing: General benefit
Source prices (unrounded): $2.9990; ministry $2.9990
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285002
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77053
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285002
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Bipazen: Formulary list price $9.0000/unit (unit not stated in source; not the patient's cost)
Ministry pays: $9.0000 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100269 · Verify on the e-Formulary ↗ (DIN 02513579)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02513579).
DIN 02513579: Bipazen
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682800007; group id 790; item number 1920; lccId None; manufacturer id KVR
Source form: Inj Sol-1mL Amp Pk; strength: 4mcg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $9.0000; ministry $9.0000
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02513579
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100269Interchangeable products
DDAVP · DIN 00873993 · not recorded
Shortage status: resolved shortage (ended 2026-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02513579
Shortage record checked 2026-09-13T08:10:21.292534+00:00
DDAVP: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13867 · Verify on the e-Formulary ↗ (DIN 00873993)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00873993).
DIN 00873993: DDAVP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682800007; group id 790; item number 1920; lccId None; manufacturer id FEI
Source form: Inj Sol-1mL Amp Pk; strength: 4mcg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00873993
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13867Interchangeable products
Bipazen · DIN 02513579 · $9.0000
Shortage status: resolved shortage (ended 2023-05-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00873993
Shortage record checked 2026-09-13T08:10:21.292534+00:00
DDAVP · DIN 00402516 · 0.1mg/mL · Nas Sol-2.5mL Pk
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.Discontinued 2021-01-29 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
DDAVP · DIN 00402516
Manufacturer: Ferring Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2021-01-29 · brand DDAVP RHINYLE · ATC H01BA02 DESMOPRESSIN · form Solution · route Nasal · ingredients DESMOPRESSIN ACETATE 0.1 MG/ML · company Ferring inc · schedule Prescription
DDAVP: Formulary list price $52.0375/unit (unit not stated in source; not the patient's cost)
Ministry pays: $52.0375 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14413 · Verify on the e-Formulary ↗ (DIN 00402516)
Source record
DIN 00402516: DDAVP
Raw flags: sec3=Y
Item: 682800005; group id 790; item number 1921; lccId None; manufacturer id FEI
Source form: Nas Sol-2.5mL Pk; strength: 0.1mg/mL
Recorded listing: General benefit
Source prices (unrounded): $52.0375; ministry $52.0375
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00402516
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14413
Shortage status: discontinued (2021-01-29, reported by FERRING INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00402516
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
DDAVP · DIN 00824305 · 0.1mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued 2022-05-31 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
DDAVP · DIN 00824305
Manufacturer: Ferring Inc.; listing date 1997-08-28
Health Canada: Cancelled post market since 2022-05-31 · brand DDAVP TABLETS 0.1MG · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.1 MG · company Ferring inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19436 · Verify on the e-Formulary ↗ (DIN 00824305)
Source record
DIN 00824305: DDAVP
Raw flags: sec3=Y
Item: 682800010; group id 790; item number 1926; lccId None; manufacturer id FEI
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $1.3217; ministry $0.6609
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00824305
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19436Interchangeable products
Apo-Desmopressin · DIN 02284030 · $0.6609
PMS-Desmopressin · DIN 02304368 · $0.6609
Shortage status: discontinued (2022-02-28, reported by FERRING INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00824305
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
DDAVP · DIN 00824143 · 0.2mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued 2022-05-31 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
DDAVP · DIN 00824143
Manufacturer: Ferring Inc.; listing date 1997-08-28
Health Canada: Cancelled post market since 2022-05-31 · brand DDAVP TABLETS 0.2MG · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.2 MG · company Ferring inc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19441 · Verify on the e-Formulary ↗ (DIN 00824143)
Source record
DIN 00824143: DDAVP
Raw flags: sec3=Y
Item: 682800011; group id 790; item number 1927; lccId None; manufacturer id FEI
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $2.6434; ministry $1.3217
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00824143
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19441Interchangeable products
Apo-Desmopressin · DIN 02284049 · $1.3217
PMS-Desmopressin · DIN 02304376 · $1.3217
Shortage status: discontinued (2022-05-31, reported by FERRING INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00824143
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued 2022-05-31 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
DDAVP Melt · DIN 02285010
Manufacturer: Ferring Inc.; listing date 2010-06-14
Health Canada: Cancelled post market since 2022-05-31 · brand DDAVP MELT · ATC H01BA02 DESMOPRESSIN · form Tablet (orally-disintegrating) · route Sublingual · ingredients DESMOPRESSIN (DESMOPRESSIN ACETATE) 240 MCG · company Ferring inc · schedule Prescription
DDAVP Melt: Formulary list price $3.9382/unit (unit not stated in source; not the patient's cost)
Ministry pays: $3.9382 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77054 · Verify on the e-Formulary ↗ (DIN 02285010)
Source record
DIN 02285010: DDAVP Melt
Raw flags: sec3=Y
Item: 682800028; group id 790; item number 1923; lccId None; manufacturer id FEI
Source form: Orally Disintegrating Tab; strength: 240mcg
Recorded listing: General benefit
Source prices (unrounded): $3.9382; ministry $3.9382
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285010
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77054
Shortage status: discontinued (2022-03-31, reported by FERRING INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285010
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
DDAVP · DIN 00836362 · 10mcg/Metered Dose · Nas Sp-2.5mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.Discontinued 2020-07-17 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
DDAVP · DIN 00836362
Manufacturer: Ferring Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2020-07-17 · brand DDAVP SPRAY · ATC H01BA02 DESMOPRESSIN · form Metered-dose aerosol · route Nasal · ingredients DESMOPRESSIN ACETATE 10 MCG/ACT · company Ferring inc · schedule Prescription
DDAVP: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9861 · Verify on the e-Formulary ↗ (DIN 00836362)
Source record
DIN 00836362: DDAVP
Raw flags: notABenefit=Y, sec3=Y
Item: 682800006; group id 790; item number 1922; lccId None; manufacturer id FEI
Source form: Nas Sp-2.5mL Pk; strength: 10mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00836362
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9861Interchangeable products
Desmopressin Spray · DIN 02242465 · $42.1661
Shortage status: discontinued (2020-07-14, reported by FERRING INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00836362
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:28 Pituitary Agents) and how they are covered
Matched class: 68:28 Pituitary Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: THYROTROPIN ALFA
68:28 Pituitary Agents
INDICATIONS AND CLINICAL USE
DDAVP injection is indicated for prophylaxis of mild hemophilia A and mild von Willebrand’s
disease Type I, and for the treatment of central diabetes insipidus.
Hemophilia A
DDAVP injection is indicated for patients with hemophilia A with Factor VIII levels greater than
5%.
DDAVP will often maintain hemostasis in patients with hemophilia A during surgical
procedures and postoperatively, when administered 45 minutes prior to the scheduled procedure.
DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or
trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.
In certain clinical situations, it may be justified to try DDAVP in patients with Factor VIII levels
between 2-5%, however, these patients should be carefully monitored.
Von Willebrand’s Disease (Type I)
DDAVP injection is indicated for patients with mild to moderate classic von Willebrand’s
Disease (Type I) with Factor VIII levels greater than 5%.
DDAVP will often maintain hemostasis in surgical procedures and postoperatively when
administered 45 minutes prior to the scheduled procedure.
…
https://pdf.hres.ca/dpd_pm/00044657.PDF
PM date: April 5, 2017
Source product: DDAVP INJ 4MCG/ML; DIN 00873993; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
PMS-Desmopressin · DIN 02304368
Shortage status: discontinued (2017-04-05, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304368
Desmopressin Spray · DIN 02242465
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-23, last updated 2026-09-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242465
For Bipazen, DDAVP: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.